Literature DB >> 22871693

Cautious optimism surrounds early clinical data for PD-1 blocker.

Cormac Sheridan.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22871693     DOI: 10.1038/nbt0812-729

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Bristol-Myers Squibb swallows last of antibody pioneers.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2009-09       Impact factor: 54.908

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

  5 in total
  8 in total

1.  Melanoma combination therapies ward off tumor resistance.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2013-08       Impact factor: 54.908

2.  Industry pursues co-stimulatory receptor immunomodulators to treat cancer.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

3.  First PD-1 inhibitor breezes across finish line.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2014-09       Impact factor: 54.908

4.  Both PD-1 ligands protect the kidney from ischemia reperfusion injury.

Authors:  Katarzyna Jaworska; Joanna Ratajczak; Liping Huang; Kristen Whalen; Mana Yang; Brian K Stevens; Gilbert R Kinsey
Journal:  J Immunol       Date:  2014-11-17       Impact factor: 5.422

Review 5.  Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer.

Authors:  Darshil T Jhaveri; Lei Zheng; Elizabeth M Jaffee
Journal:  Semin Oncol       Date:  2014-07-22       Impact factor: 4.929

Review 6.  Microscale Thermophoresis as a Tool to Study Protein Interactions and Their Implication in Human Diseases.

Authors:  Romain Magnez; Christian Bailly; Xavier Thuru
Journal:  Int J Mol Sci       Date:  2022-07-12       Impact factor: 6.208

7.  To be, or not to be immunocompetent.

Authors:  Hans-Dieter Volk; Petra Reinke
Journal:  Crit Care       Date:  2013-09-13       Impact factor: 9.097

8.  PD-1/PD-L1 binding studies using microscale thermophoresis.

Authors:  Romain Magnez; Bryan Thiroux; Solenne Taront; Zacharie Segaoula; Bruno Quesnel; Xavier Thuru
Journal:  Sci Rep       Date:  2017-12-15       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.